Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 360824
Title The precalence of the metabolic syndrome is increades in patients with GH deficiency, irrespective of long-term substition with recombinant human GH
Author(s) Klaauw, A.A.; Biermasz, N.R.; Feskens, E.J.M.; Bos, M.B.; Smit, J.W.; Roelfsema, F.; Corssmit, E.P.; Pijl, H.; Romijn, J.A.; Pereira, A.M.
Source European Journal of Endocrinology 156 (2007)4. - ISSN 0804-4643 - p. 455 - 462.
Department(s) Chair Nutrition and Disease
Chair Nutrition and Health over the Lifecourse
Publication type Refereed Article in a scientific journal
Publication year 2007
Keyword(s) growth-hormone gh - cardiovascular risk-factors - replacement therapy - hypopituitary patients - insulin sensitivity - cushings-disease - adults - cholesterol - resistance - mortality
Abstract Objectives: Many reports demonstrate improvements in cardiovascular risk factors during GH replacement (rhGH) in adult GH deficiency (GHD). However, it remains to be determined to what extent these changes translate into a reduction of increased cardiovascular morbidity and mortality. The aim of this study was to evaluate the effects of long-term rhGH replacement on the prevalence of the metabolic syndrome (MS). Design, settings, main outcome measures: The MS was scored by the National Cholesterol Education Program-Adult Treatment Panel III definition in 50 consecutive GHD patients (45 9 years of age), before and after 2 and 5 years of rhGH replacement, and the data of untreated patients were compared with the general population using data from a Dutch population-based study (n = 1062, 44 +/- 8 years of age). Results: Hypertriglyceridaemia (46.0 vs 18.5%, P <0.0001), hypertension (66.0 vs 35.5%, P <0.0001) and abdominal obesity (38.0 vs 23.4%, P=0.0178) were more prevalent in untreated patients when compared with controls, resulting in a higher prevalence of the MS in patients (38.0 vs 15.7%, P <0.0001). During rhGH replacement at a mean dose of 0.5 +/- 0.2 mg/day resulting in IGF-I concentrations in the normal age-adjusted reference range, mean high-density lipoprotein cholesterol level increased compared with baseline (P <0.001). However, the prevalence of (components of) the MS did not change after 2 or 5 years of treatment with rhGH. Conclusion: In this study, the prevalence of the MS in patients with GHD is increased compared with healthy controls, irrespective of rhGH replacement.
There are no comments yet. You can post the first one!
Post a comment
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.